Protalix BioTherapeutics (PLX) Revenue Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 77.85% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -25.02% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 42.02% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 59.40% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -37.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 76.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.80% |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -17.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.22% |
| Mar 31, 2026 | 52.12% |
| Dec 31, 2025 | 1.92% |
| Sep 30, 2025 | 7.97% |
| Jun 30, 2025 | 21.39% |
| Mar 31, 2025 | -14.33% |
| Dec 31, 2024 | 28.69% |
| Sep 30, 2024 | 14.21% |
| Jun 30, 2024 | 27.99% |
| Mar 31, 2024 | -30.82% |
| Dec 31, 2023 | -18.67% |
| Sep 30, 2023 | -1.39% |
| Jun 30, 2023 | 47.33% |
| Mar 31, 2023 | -23.77% |
| Dec 31, 2022 | -14.89% |
| Sep 30, 2022 | -0.15% |
| Jun 30, 2022 | -10.59% |
| Mar 31, 2022 | 15.50% |
| Dec 31, 2021 | 69.48% |
| Sep 30, 2021 | 162.95% |